Sunday, June 07, 2026
In Detail Full day, Sunday, June 07, 2026, Timezone: America/Chicago
Florian Lordick Elected ESMO President 2029–2030
oncodaily - Professor Florian Lordick has been elected President of the European Society for Medical Oncology for the 2029–2030 term, marking a new leadership chapter for one of the world’s leading oncology […]
AI Summary: Florian Lordick will serve as ESMO president for 2029–2030, pledging to prioritise precision oncology, workforce development and stronger European collaboration. Colleagues praise his vision for translating research into practice and amplifying policy advocacy; expectations include initiatives to close care gaps and bolster international partnerships — because someone has to herd this many oncologists.
Short-term fasting could boost chemo response in ovarian cancer, study suggests
medicalxpress - A simple change in meal timing may help improve outcomes for women with the most common and aggressive form of ovarian cancer, a new study suggests.
AI Summary: ASCO‑presented research indicates short‑term fasting around chemotherapy cycles can enhance response in high‑grade serous ovarian cancer versus a regular diet, altering tumor biology to increase chemosensitivity. The findings suggest a low‑cost adjunct to standard treatment, though real‑world feasibility and longer‑term benefits require larger trials — fasting as a potential therapeutic booster, not a fad.
NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer
oncodaily - The NRG-GY018 trial returned to the ASCO 2026 stage with the question that matters more than any progression endpoint: do patients actually live longer? Presented by Ramez N. Eskander, MD […]
AI Summary: Updated results from the NRG‑GY018 trial show adding pembrolizumab to chemotherapy sustains an overall survival benefit in advanced endometrial cancer. The follow‑up confirms the durability of immunotherapy’s impact and supports integrating checkpoint inhibitors into standard regimens for eligible patients, potentially changing practice for a cancer type that’s long hungered for better systemic options.
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Drug Pricing, Diagnostics, Cancer Research, Medicaid and look for the RSS link.
StackHealth Time Machine
More StackHealth